Myelodysplastic syndromes (MDS) represent a group of heterogeneous diseases which remain a challenge to treat, and several novel therapies are being explored for the treatment of patients, especially those with relapsed/refractory (R/R) or high-risk disease. Immune therapies including CAR-T therapy and monoclonal antibodies are a promising option for patients, and are being evaluated in MDS following their success in other hematological malignancies. However, several challenges need to be addressed before these can be applied in clinical practice.
In this podcast, you will hear from experts David Sallman, MD, Moffit Cancer Center, Tampa, FL, Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, and Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, who discuss novel immune therapies being explored in MDS, emphasizing the challenges and opportunities for CAR-T therapy in this space.
The post Novel immune therapies in MDS and challenges in this space appeared first on VJHemOnc.
